Company research
QUEST DIAGNOSTICS INC
CIK 1022079Updated Sep 26, 2026
SecurityDGX · NYSE · equity
Name history
CORNING CLINICAL LABORATORIES INC · through Mar 19, 1997
DGX price & chart
Loading TradingView…
NYSE:DGX on TradingView ↗About the company
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www. QuestDiagnostics.com.
In the news
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 News provided by Quest Diagnostics Oct 21, 2025, 06:45 ET Share this article Share to X Share this article Share to X Third quarter revenues of $2.82 billion, up 13.1% from 2024 Third quarter reported ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 16,225,000,000Source | 16,153,000,000Source | 14,022,000,000Source | 12,837,000,000Source |
| Property, Plant and Equipment, NetUSD | 2,203,000,000Source | 2,113,000,000Source | 1,816,000,000Source | 1,766,000,000Source |
| GoodwillUSD | 8,945,000,000Source | 8,856,000,000Source | 7,733,000,000Source | 7,220,000,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,636,000,000Source | 1,763,000,000Source | 1,166,000,000Source | 1,092,000,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 420,000,000Source | 549,000,000Source | 686,000,000Source | 315,000,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,408,000,000Source | 1,304,000,000Source | 1,210,000,000Source | 1,195,000,000Source |
| Inventory, NetUSD | 189,000,000Source | 188,000,000Source | 190,000,000Source | 192,000,000Source |
| Assets, CurrentUSD | 2,378,000,000Source | 2,392,000,000Source | 2,372,000,000Source | 1,898,000,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 361,000,000Source | 351,000,000Source | 286,000,000Source | 196,000,000Source |
| Operating Lease, Right-of-Use AssetUSD | 657,000,000Source | 651,000,000Source | 602,000,000Source | 585,000,000Source |
| Other Assets, NoncurrentUSD | 270,000,000Source | 255,000,000Source | 198,000,000Source | 144,000,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 2,000,000Source | 2,000,000Source | 2,000,000Source | 2,000,000Source |
| Retained Earnings (Accumulated Deficit)USD | 9,994,000,000Source | 9,360,000,000Source | 8,825,000,000Source | 8,290,000,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -27,000,000Source | -88,000,000Source | -14,000,000Source | -21,000,000Source |
| Stockholders' Equity Attributable to ParentUSD | 7,170,000,000Source | 6,778,000,000Source | 6,307,000,000Source | 5,893,000,000Source |
| Additional Paid in Capital, Common StockUSD | 2,381,000,000Source | 2,361,000,000Source | 2,320,000,000Source | 2,295,000,000Source |
| Liabilities and EquityUSD | 16,225,000,000Source | 16,153,000,000Source | 14,022,000,000Source | 12,837,000,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,278,000,000Source | 2,169,000,000Source | 1,815,000,000Source | 1,551,000,000Source |
| Operating Lease, Liability, CurrentUSD | 174,000,000Source | 173,000,000Source | 153,000,000Source | 153,000,000Source |
| Operating Lease, Liability, NoncurrentUSD | 537,000,000Source | 535,000,000Source | 503,000,000Source | 489,000,000Source |
| Other Liabilities, NoncurrentUSD | 957,000,000Source | 938,000,000Source | 876,000,000Source | 812,000,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 36,000,000Source | 35,000,000Source | 35,000,000Source | 37,000,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 338,000,000Source | 306,000,000Source | 287,000,000Source | 392,000,000Source |
| Deferred Tax Liabilities, NetUSD | 344,000,000Source | 250,000,000Source | 270,000,000Source | 295,000,000Source |
| Dividends Payable, CurrentUSD | 89,000,000Source | 84,000,000Source | 79,000,000Source | 74,000,000Source |
| Dividends PayableUSD | 89,000,000Source | 84,000,000Source | 79,000,000Source | 74,000,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 504,000,000Source | 602,000,000Source | 303,000,000Source | 2,000,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 5,167,000,000Source | 5,615,000,000Source | 4,410,000,000Source | 3,978,000,000Source |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountUSD | 80,000,000Source | 83,000,000Source | 76,000,000Source | 77,000,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 1,046,000,000Source | 921,000,000Source | 908,000,000Source | 1,015,000,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 570,000,000Source | 493,000,000Source | 439,000,000Source | 437,000,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 88,000,000Source | 88,000,000Source | 77,000,000Source | 77,000,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 106,000,000Source | 71,000,000Source | 15,000,000Source | -246,000,000Source |
| Deferred Income Tax Expense (Benefit)USD | 105,000,000Source | 13,000,000Source | -49,000,000Source | 1,000,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 1,886,000,000Source | 1,334,000,000Source | 1,272,000,000Source | 1,718,000,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 101,000,000Source | 2,164,000,000Source | 611,000,000Source | 144,000,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -631,000,000Source | -2,548,000,000Source | -1,061,000,000Source | -543,000,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | 3,000,000Source | -41,000,000Source | 42,000,000Source | -5,000,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 527,000,000Source | 425,000,000Source | 408,000,000Source | 404,000,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 45,000,000Source | 24,000,000Source | 28,000,000Source | 28,000,000Source |
| Payments for Repurchase of Common StockUSD | 450,000,000Source | 151,000,000Source | 275,000,000Source | 1,408,000,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -1,388,000,000Source | 1,084,000,000Source | 160,000,000Source | -1,732,000,000Source |
| Payments of Ordinary Dividends, Common StockUSD | 353,000,000Source | 331,000,000Source | 314,000,000Source | 305,000,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 39,000,000Source | 21,000,000Source | 14,000,000Source | -39,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -129,000,000Source | -137,000,000Source | 371,000,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 420,000,000Source | 549,000,000Source | 686,000,000Source | 315,000,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 280,000,000Source | 262,000,000Source | 134,000,000Source | 156,000,000Source |
| Income Taxes Paid, NetUSD | 169,000,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,000,000Source | -7,000,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 154,000,000Source | 127,000,000Source | 108,000,000Source | 120,000,000Source |
| DepreciationUSD | 416,000,000Source | 366,000,000Source | 331,000,000Source | 317,000,000Source |
| Dividends Payable, CurrentUSD | 89,000,000Source | 84,000,000Source | 79,000,000Source | 74,000,000Source |
| Dividends PayableUSD | 89,000,000Source | 84,000,000Source | 79,000,000Source | 74,000,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | 19,000,000Source | 18,000,000Source | 20,000,000Source | -55,000,000Source |
| GoodwillUSD | 8,945,000,000Source | 8,856,000,000Source | 7,733,000,000Source | 7,220,000,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | 42,000,000Source | 19,000,000Source | 26,000,000Source | 44,000,000Source |
| Income Tax Expense (Benefit)USD | 314,000,000Source | 273,000,000Source | 248,000,000Source | 264,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | 992,000,000Source | 871,000,000Source | 854,000,000Source | 946,000,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 54,000,000Source | 50,000,000Source | 54,000,000Source | 69,000,000Source |
| Nonoperating Income (Expense)USD | -238,000,000Source | -171,000,000Source | -132,000,000Source | -193,000,000Source |
| Other Nonoperating Income (Expense)USD | 26,000,000Source | 30,000,000Source | 20,000,000Source | -55,000,000Source |
| Other Operating Income (Expense), NetUSD | 12,000,000Source | -1,000,000Source | -41,000,000Source | -11,000,000Source |
| Proceeds from Stock Options ExercisedUSD | 79,000,000Source | 73,000,000Source | 72,000,000Source | 123,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 11,035,000,000Source | 9,872,000,000Source | 9,252,000,000Source | 9,883,000,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 1,967,000,000Source | 1,770,000,000Source | 1,642,000,000Source | 1,874,000,000Source |
| Operating Income (Loss)USD | 1,556,000,000Source | 1,346,000,000Source | 1,262,000,000Source | 1,428,000,000Source |
| Other Nonoperating Income (Expense)USD | 26,000,000Source | 30,000,000Source | 20,000,000Source | -55,000,000Source |
| Income Tax Expense (Benefit)USD | 314,000,000Source | 273,000,000Source | 248,000,000Source | 264,000,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 54,000,000Source | 50,000,000Source | 54,000,000Source | 69,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | 992,000,000Source | 871,000,000Source | 854,000,000Source | 946,000,000Source |
| Earnings Per Share, BasicUSD per share | 8.87Source | 7.78Source | 7.59Source | 8.1Source |
| Earnings Per Share, DilutedUSD per share | 8.75Source | 7.69Source | 7.49Source | 7.97Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 111,000,000Source | 111,000,000Source | 112,000,000Source | 116,000,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 113,000,000Source | 113,000,000Source | 113,000,000Source | 118,000,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 154,000,000Source | 127,000,000Source | 108,000,000Source | 120,000,000Source |
| Costs and ExpensesUSD | 9,479,000,000Source | 8,526,000,000Source | 7,990,000,000Source | 8,455,000,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 1,200,000,000Source | 1,100,000,000Source | 1,100,000,000Source | 1,200,000,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 42,000,000Source | 19,000,000Source | 26,000,000Source | 44,000,000Source |
| Interest ExpenseUSD | — | — | 163,000,000Source | 148,000,000Source |
| InterestExpenseOperatingUSD | 277,000,000Source | 226,000,000Source | — | — |
| Interest Income (Expense), NetUSD | -264,000,000Source | -201,000,000Source | -152,000,000Source | -138,000,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -264,000,000Source | -201,000,000Source | — | — |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | 988,000,000Source | 866,000,000Source | 850,000,000Source | 942,000,000Source |
| Nonoperating Income (Expense)USD | -238,000,000Source | -171,000,000Source | -132,000,000Source | -193,000,000Source |
| Other Operating Income (Expense), NetUSD | 12,000,000Source | -1,000,000Source | -41,000,000Source | -11,000,000Source |
Filing attachments
dgx063020268-kex991.htm · 8-K · 2026-07-23
EX-99.1 2 dgx063020268-kex991.htm EX-99.1 Document Exhibit 99.1 Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 • Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth • Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted diluted EPS of $3.12, up 19.1% from 2025 • Full year 2026 revenues now expected to be between $11.95 billion…
Read attachment ↗tm2613096d2_ex4-2.htm · 8-K · 2026-05-08
EX-4.2 2 tm2613096d2_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 QUEST DIAGNOSTICS INCORPORATED, as Issuer and THE BANK OF NEW YORK MELLON, as Trustee Twenty-Fourth Supplemental Indenture Dated as of May 6, 2026 TABLE OF CONTENTS Page Article I. DEFINITIONS …
Read attachment ↗tm2613096d1_ex99-1.htm · 8-K · 2026-05-01
EX-99.1 3 tm2613096d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Quest Diagnostics Prices $500 Million of Senior Notes SECAUCUS, NJ - April 27, 2026 /PRNewswire/ - Quest Diagnostics Incorporated (NYSE: DGX) (the “Company”), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under Quest Diagnostics' shelf registration statement. Quest Diagnostics expects to rece…
Read attachment ↗dgx033120268-kex991.htm · 8-K · 2026-04-21
EX-99.1 2 dgx033120268-kex991.htm EX-99.1 Document Exhibit 99.1 Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 • First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth • First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025 • Full year 2026 reported diluted EPS now expected to be between $9.58 a…
Read attachment ↗dgx093020258-kex991.htm · 8-K · 2025-10-21
EX-99.1 2 dgx093020258-kex991.htm EX-99.1 Document Exhibit 99.1 Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 • Third quarter revenues of $2.82 billion, up 13.1% from 2024 • Third quarter reported diluted earnings per share ("EPS") of $2.16, up 8.5% from 2024; and adjusted diluted EPS of $2.60, up 13.0% from 2024 • Year-to-date cash provided by operations of $1.4 billion, up 63.1% from 2024 • Full year 2025 reported diluted EPS now …
Read attachment ↗dgx063020258-kex991.htm · 8-K · 2025-07-22
EX-99.1 2 dgx063020258-kex991.htm EX-99.1 Document Exhibit 99.1 Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 • Second quarter revenues of $2.76 billion, up 15.2% from 2024 • Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024 • Year-to-date cash provided by operations of $858 million, up 67.1% from 2024 • Full year 2025 reported diluted EPS …
Read attachment ↗